HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating for Voyager Therapeutics (NASDAQ:VYGR) and maintained a price target of $30.
August 20, 2024 | 10:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Voyager Therapeutics, maintaining a $30 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $30 price target by a reputable analyst suggests positive sentiment and potential upside for Voyager Therapeutics' stock. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100